title: Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes.
abstract: BACKGROUND
  Tumor human papillomavirus (HPV) status has emerged as one of the most powerful prognostic factors for disease control and survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). We reviewed our experience in patients with OPSCC and known tumor HPV status treated with definitive chemoradiotherapy (CRT).
  
  
  METHODS
  Patients with stage III-IVb OPSCC and known tumor HPV status treated with CRT between 2006 and 2011 were identified from an IRB approved registry for this retrospective review. Outcomes were estimated using the Kaplan-Meier method and compared between HPV-positive and negative patients using the log-rank test.
  
  
  RESULTS
  Of the 121 pts (89% male, 93% Caucasian) included in this study, median age was 57 (range: 40-73) and median follow-up was 21 months (range: 6-63). Ninety-seven (80%) patients were HPV-positive and 24 (20%) were HPV-negative. Primary site was base of tongue (55%), tonsil (44%), and oropharyngeal wall (2%). Two year rates of locoregional recurrence (3% vs. 26%; p = 0.002), disease free survival (93% vs. 64%; p = 0.001) and overall survival (94% vs 73%; p = 0.002) were superior in HPV-positive patients, while rates of distant recurrence were similar (3% vs. 5%; p = 0.98). While acute toxicities were similar between both groups, patients with HPV-positive disease were more likely to resume a normal diet (90% vs. 65%; p = 0.017) at last follow up. Also, no HPV-positive patient required a feeding tube beyond 6 months after treatment, compared with 24% of HPV-negative patients.
  
  
  CONCLUSIONS
  Definitive CRT produces excellent rates of disease control with minimal late toxicity for patients with HPV-positive OPSCC. Studies of OPSCC should account for tumor HPV status when identifying factors prognostic for outcome.
authors.forename: Trevor J
authors.initials: TJ
authors.lastname: Bledsoe
authors.forename: Anisha R
authors.initials: AR
authors.lastname: Noble
authors.forename: Grant K
authors.initials: GK
authors.lastname: Hunter
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Rybicki
authors.forename: Aaron
authors.initials: A
authors.lastname: Hoschar
authors.forename: Deborah J
authors.initials: DJ
authors.lastname: Chute
authors.forename: Jerrold P
authors.initials: JP
authors.lastname: Saxton
authors.forename: John F
authors.initials: JF
authors.lastname: Greskovich
authors.forename: David J
authors.initials: DJ
authors.lastname: Adelstein
authors.forename: Shlomo A
authors.initials: SA
authors.lastname: Koyfman
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000628:therapy* / Q000821:virology; D059248:Chemoradiotherapy / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009959:Oropharyngeal Neoplasms / Q000628:therapy* / Q000821:virology; D030361:Papillomavirus Infections / Q000150:complications*; D012189:Retrospective Studies